High likelihood for a stock purchase by Cathie Wood following Trump's move.
In a move that underscores her confidence in the future of genomics and artificial intelligence (AI), Cathie Wood, the visionary CEO of ARK Invest, has made significant investments in key companies.
Wood's latest purchase through her ARK Innovation ETF includes over $2.98 million worth of shares in Illumina, a leading player in DNA sequencing technologies. Wood views Illumina as a pioneer in the field, with substantial growth potential in precision medicine, genomic research, and emerging applications in agriculture and environmental science. The company's dominant 80% market share and attractive valuation, about 72% below its five-year average Price/Earnings ratio, support Wood's conviction in Illumina's long-term price upside. Analysts estimate a potential 18% increase from current levels for the company, reflecting Wood's belief that Illumina is poised to lead a multi-trillion-dollar healthcare transformation.
Regarding CRISPR Therapeutics and Pacific Biosciences, Wood's current stance is not explicitly clear from the latest information. No direct mention of recent trades or outlook comments related to these stocks was found in the search results.
In terms of Amazon, no recent notable investments or adjustments in Amazon shares have been made by Wood within her key ETFs, according to the available data.
Wood's strategy appears to focus on high-conviction, better-valued biotech stocks like Illumina and AI leaders like Nvidia, while trimming more speculative or less favourite holdings like Guardant Health and Rocket Lab.
The gene sequencing market is projected to grow by around 20% annually until 2030, according to Grand View Research. All three companies, Illumina, CRISPR Therapeutics, and Pacific Biosciences, are active players in this market.
Interestingly, the CEO of the publisher Börsenmedien AG, Mr. Bernd Förtsch, holds positions in CRISPR Therapeutics and Palantir Technologies, while the board of the same publisher, Mr. Leon Müller, has positions in Amazon and Tesla.
In other news, Wood sold over 170,000 shares of AI company Palantir and over 85,000 shares of Tesla after the election. On November 7th, she bought over 100,000 shares of biotech company Pacific Biosciences and over 74,000 shares of CRISPR Therapeutics. Wood also purchased over 76,000 shares of genetic engineering company Illumina on the same day.
The highest price target for Pacific Biosciences is $7, which represents a potential increase of up to 186%. The highest price target for CRISPR Therapeutics is $95, which represents a potential increase of up to 80%. The highest price target for Illumina is $254, which represents a potential increase of up to 64%.
A recent publication advises selling Nvidia stocks before Friday, but Wood's position on this matter remains unclear. It is also worth noting that Wood, a 68-year-old investor, has shown support for the election of Donald Trump as US President.
These investments and sales underscore Wood's strategic approach and her belief in the potential of these companies to drive growth and transformation in their respective industries. As always, investors are advised to conduct their own due diligence before making investment decisions.
Investing in technology companies aligns with Cathie Wood's strategic approach, as evidenced by her recent purchase of Illumina shares. Additionally, Wood's portfolio contains stocks from AI companies like Palantir and Tesla, suggesting a focus on the intersection of finance, investing, and emerging technologies.
